Today 18 European academic partners and 3 pharmaceutical companies are launching a new project under the Innovative Medicines Initiative (IMI) funded New Drugs 4 Bad Bugs (ND4BB) program: COMBACTE-CARE.
COMBACTE-CARE (Combatting Bacterial resistance in Europe-Carbapenem-Resistance) will bring highly innovative studies and activities related to the treatment of patients with infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). Being very difficult to treat and sometimes deadly, CRE are considered to be one of the most dangerous resistant bacteria in the world. University Medical Center Utrecht is the project’s managing entity.
Prof. dr. Jacco van Rheenen received a grant of 2 million euro from the European Research Council (ERC). The professor in Intravital Microscopy of the UMC Utrecht and the Hubrecht Institute received this ‘Consolidator Grant’ to further strengthen his research into the spreading of tumor cells in the next 5 years.
A pneumococcal vaccine helps prevent pneumonia among people over the age of 65. Research among some 85,000 Dutch subjects shows that vaccination halves the number of hospitalizations due to infection with this bacterium. Researchers at University Medical Center (UMC) of Utrecht, in collaboration with Pfizer, published these results today in the New England Journal of Medicine. A guideline has been drafted in the U.S. that recommends that all elderly people receive the vaccine.
Researchers at UMC Utrecht are developing an innovative cancer treatment with the help of a grant from Alpe d’HuZes/Dutch Cancer Society (KWF) of nearly 300,000 euros. The treatment involves the injection of radioactive beads into tumors, thereby enabling a very precise localized radiotherapy.
Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB). ND4BB has been launched to stimulate antibiotic development in Europe. COMBACTE-MAGNET (Combatting Bacterial Resistance in Europe - Molecules Against Gram-Negative Infections) will bring highly innovative studies and activities related to prevention and treatment of infections caused by multi-drug resistant Gram-negative bacteria. University Medical Center Utrecht is the project’s managing entity.
Professor Marc Bonten from the UMC Utrecht receives the 2015 Award for Excellence in Clinical Microbiology and Infectious Diseases. The award signifies his contributions in Clinical Microbiology, Infectious Diseases and Infection Control.
Researchers at the Hubrecht Institute and the University Medical Center (UMC) Utrecht successfully developed a culturing system for human liver stem cells as well as stem cells from pancreatic cancer. They describe the development of these culturing systems in two articles in this week’s edition of Cell magazine.
The European Research Council (ERC) has awarded two grants to researchers at the UMC Utrecht. Radiologist Jeroen Hendrikse and microbiologist Suzan Rooijakkers each receive 1.5 million euro for the next five years to establish a research line of their own. The ERC Starting Grant is considered a major grant and is awarded annually to a select group of promising researchers.
Cancer genes may also be responsible for the development of congenital disorders. This is put forth by researchers of the Hubrecht Instituut and UMC Utrecht in the scientific journal Cell Reports on the 12th of December 2014.
Utrecht University and University Medical Center Utrecht offer their first online postgraduate master in Epidemiology, Epidemiology Online, starting February 1st 2015. This enables researchers to study anytime, anywhere in the world, simultaneous with a busy career and social life.